AR054369A1 - Compuestos de imidazol condensado y su uso como inhibidores de aldosterona sintasa - Google Patents
Compuestos de imidazol condensado y su uso como inhibidores de aldosterona sintasaInfo
- Publication number
- AR054369A1 AR054369A1 ARP060102235A ARP060102235A AR054369A1 AR 054369 A1 AR054369 A1 AR 054369A1 AR P060102235 A ARP060102235 A AR P060102235A AR P060102235 A ARP060102235 A AR P060102235A AR 054369 A1 AR054369 A1 AR 054369A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cr3r4
- alkylcarbonyl
- heterocyclyl
- oxo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Un proceso para prepararlos y al uso de estos compuestos como medicamentos, particularmente como inhibidores de la aldosterona sintasa. Reivindicacion 1: Compuesto de la formula general (1) donde A es arlo o heterociclilo; X es CR3R4 o, si Y es CR3R4, es alternativamente un enlace; Y es CR3R4, O, S(O)m o NR5; Z es CR3R4 o a) si Y es CR3R4, es alternativamente O, S(O)m o NR5; o b) si Y es S(O)m, es alternativamente NR5; o c) si Y es NR5, es alternativamente S(O)m; R es alcoxi C1-8, alquil C1-8, halogeno, trifluormetilo, tri-alquil C1-4-sililo, deuterio o H; R1 es alcoxi C1-8, alcoxi C1-8-carbonilo, alquil C1-8, mono- y di-alquil C1-8-amino, mono- y di-alquil C1-8-aminocarbonilo, alquil C0-8-carbonilo, amino, carbamoílo, carboxi- alquil C1-4, carboxilo, ciano, halogeno, oxo, trifluormetilo, trifluormetoxi, heterociclilo o arilo, dichos radicales pueden estar sustituidos con 1 a 4 alcoxi C1-8, alcoxi C1-8-carbonilo, alquil C1-8, alquil C0-8-carbonilo, tri-alquil C1-4-sililo, alquil C1-8-sulfonilo, arilo, ciano, halogeno, heterociclilo, oxo, trifluormetilo o trifluormetoxi; R2 a) es, independientemente uno del otro, alquil C1-8, mono- y di-alquil C1-8-amino, mono- y di-alquil C1-8-aminocarbonilo, alquil C0-8-carbonilo, alcoxi C1-8, alcoxi C1-8-carbonilo, amino, carbamoílo, carboxi-alquil C1-4, carboxilo, ciano, halogeno, oxo, trifluormetilo, trifluormetoxi, H, heterociclilo o arilo, dichos radicales pueden estar sustituidos con 1 a 4 alcoxi C1-8, alcoxi c1-8- carbonilo, alquil C1-8, alquil C0-8-carbonilo, tri-alquil C1-4-sililo, alquil C1-8-sulfonilo, arilo, ciano, halogeno, heterociclilo, oxo, trifluormetilo o trifluormetoxi; o b) junto con R1 es un anillo heterocíclico de 5 a 6 miembros fusionado; R3 es H o alquil C1-8; R4 a) es H o alquil C1-8; o b) junto con R3 es oxo; R5 es H, alquil C1-8 o alquil C0-8-carbonilo; m es un numero 0, 1 o 2; n es un numero 0, 1 o 2; p es un numero 1 o 2; y sus sales, preferiblemente sus sales farmacéuticamente utiles.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH9212005 | 2005-05-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR054369A1 true AR054369A1 (es) | 2007-06-20 |
Family
ID=36782416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060102235A AR054369A1 (es) | 2005-05-31 | 2006-05-30 | Compuestos de imidazol condensado y su uso como inhibidores de aldosterona sintasa |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20100168145A1 (es) |
| EP (1) | EP1885359A1 (es) |
| JP (1) | JP2008542333A (es) |
| CN (1) | CN101184485A (es) |
| AR (1) | AR054369A1 (es) |
| BR (1) | BRPI0611309A2 (es) |
| CA (1) | CA2609930A1 (es) |
| IL (1) | IL187646A0 (es) |
| TW (1) | TW200716105A (es) |
| WO (1) | WO2006128851A1 (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200612947A (en) * | 2004-05-28 | 2006-05-01 | Speedel Experimenta Ag | Organic compounds |
| TW200716636A (en) * | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
| AR056888A1 (es) * | 2005-12-09 | 2007-10-31 | Speedel Experimenta Ag | Derivados de heterociclil imidazol |
| TW200813071A (en) * | 2006-04-12 | 2008-03-16 | Speedel Experimenta Ag | Spiro-imidazo compounds |
| AU2010251967B9 (en) | 2009-05-28 | 2014-04-03 | Novartis Ag | Substituted aminopropionic derivatives as neprilysin inhibitors |
| SG176010A1 (en) | 2009-05-28 | 2011-12-29 | Novartis Ag | Substituted aminobutyric derivatives as neprilysin inhibitors |
| JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
| US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
| US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
| AU2012282109B2 (en) | 2011-07-08 | 2016-06-23 | Novartis Ag | Method of treating atherosclerosis in high triglyceride subjects |
| UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
| JP6295277B2 (ja) | 2013-02-14 | 2018-03-14 | ノバルティス アーゲー | Ｎｅｐ（中性エンドペプチダーゼ）阻害剤としての置換ビスフェニルブタン酸ホスホン酸誘導体 |
| AU2014293387B2 (en) | 2013-07-25 | 2017-04-20 | Novartis Ag | Bioconjugates of synthetic apelin polypeptides |
| KR20160031551A (ko) | 2013-07-25 | 2016-03-22 | 노파르티스 아게 | 심부전의 치료를 위한 시클릭 폴리펩티드 |
| EA201791668A1 (ru) | 2015-01-23 | 2017-11-30 | Новартис Аг | Синтетические конъюгаты апелина с жирной кислотой с улучшенным периодом полураспада |
| JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
| UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
| CN113166101A (zh) | 2018-11-27 | 2021-07-23 | 诺华股份有限公司 | 作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂的环状五聚体化合物 |
| CN113166204A (zh) | 2018-11-27 | 2021-07-23 | 诺华股份有限公司 | 作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂的环状肽 |
| UY38485A (es) | 2018-11-27 | 2020-06-30 | Novartis Ag | Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación |
| WO2023084449A1 (en) | 2021-11-12 | 2023-05-19 | Novartis Ag | Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder |
| AR127698A1 (es) | 2021-11-23 | 2024-02-21 | Novartis Ag | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057521A (en) * | 1988-10-26 | 1991-10-15 | Ciba-Geigy Corporation | Use of bicyclic imidazole compounds for the treatment of hyperaldosteronism |
| JPH0971586A (ja) * | 1995-09-07 | 1997-03-18 | Yamanouchi Pharmaceut Co Ltd | 新規な二環性縮合イミダゾール誘導体 |
| EP1565463B1 (en) * | 2002-11-18 | 2008-06-11 | Novartis AG | Imidazo[1,5a] pyridine derivatives and methods for treating aldosterone mediated diseases |
| US20080076794A1 (en) * | 2004-05-28 | 2008-03-27 | Peter Herold | Heterocyclic Compounds And Their Use As Aldosterone Synthase Inhibitors |
| TW200716634A (en) * | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| GT200600381A (es) * | 2005-08-25 | 2007-03-28 | Compuestos organicos |
-
2006
- 2006-05-29 TW TW095119001A patent/TW200716105A/zh unknown
- 2006-05-30 CN CNA2006800190067A patent/CN101184485A/zh active Pending
- 2006-05-30 WO PCT/EP2006/062694 patent/WO2006128851A1/en not_active Application Discontinuation
- 2006-05-30 AR ARP060102235A patent/AR054369A1/es unknown
- 2006-05-30 US US11/921,313 patent/US20100168145A1/en not_active Abandoned
- 2006-05-30 BR BRPI0611309-5A patent/BRPI0611309A2/pt not_active IP Right Cessation
- 2006-05-30 CA CA002609930A patent/CA2609930A1/en not_active Abandoned
- 2006-05-30 EP EP06763349A patent/EP1885359A1/en not_active Withdrawn
- 2006-05-30 JP JP2008514082A patent/JP2008542333A/ja active Pending
-
2007
- 2007-11-26 IL IL187646A patent/IL187646A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL187646A0 (en) | 2008-08-07 |
| EP1885359A1 (en) | 2008-02-13 |
| TW200716105A (en) | 2007-05-01 |
| WO2006128851A1 (en) | 2006-12-07 |
| US20100168145A1 (en) | 2010-07-01 |
| JP2008542333A (ja) | 2008-11-27 |
| CN101184485A (zh) | 2008-05-21 |
| BRPI0611309A2 (pt) | 2011-05-31 |
| CA2609930A1 (en) | 2006-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR054369A1 (es) | Compuestos de imidazol condensado y su uso como inhibidores de aldosterona sintasa | |
| AR053739A1 (es) | Compuestos espiro condensados como inhibidores de la aldosterona sintasa | |
| AR066691A1 (es) | Compuestos espiro heterociclicos derivados de imidazol. composiciones farmaceuticas. | |
| AR047538A1 (es) | Piridazinonas como antagonistas de las integrinas alfa4 | |
| AR057040A1 (es) | Compuestos espiro heterociclicos y composicion farmaceutica | |
| ECSP034865A (es) | Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas | |
| AR059778A1 (es) | Compuestos de pirrolotriazina inhibidores de quinasas p38,composiciones farmaceuticas que los contienen y usos en gran variedad de procesos inflamatorios. | |
| AR067443A1 (es) | Derivados heterociclicos de n-benziloxazolidinonas potenciadores de receptores de glutamato mglur2, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento de trastornos del sistema nervioso central | |
| AR049388A1 (es) | Heterociclos como inhibidores de aldosterona sintasa | |
| BRPI0418639B8 (pt) | compostos inibidores de dipeptidil peptidase, assim como composição farmacêutica contendo os mesmos | |
| ES2546502T3 (es) | 2,6-Diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o JAK quinasas | |
| NO20070122L (no) | Quinazolinonderivater anvendelige som vanilloidantagonister | |
| PE20151413A1 (es) | Inhibidores de bmi-1 de pirimidina inversa sustituida | |
| AR037900A1 (es) | Alfa-cianoacrilatos | |
| AR060590A1 (es) | Compuestos imidazo | |
| UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
| UY30897A1 (es) | Derivados de pentafluorotiobenzamidoacetonitrilo, composiciones conteniéndolos y aplicaciones | |
| AR049126A1 (es) | Derivados de 5, 6, 7, 8 - tetrahidroimidazo[1,5a]piridina con actividad inhibitoria de la aldosterona sintasa, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del hiperaldosterismo y del sindrome de cushing. | |
| AR072047A1 (es) | Compuestos heterociclicos utiles para inhibir la adn girasa | |
| ATE431333T1 (de) | Amino-propanolderivate | |
| PE20140703A1 (es) | Derivados de heteroarilo como moduladores de nachr alfa 7 | |
| CO6260074A2 (es) | Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones como inhibidores de cinasa | |
| UY30127A1 (es) | Derivados de acidos antranilicos fenoxi y feniltio, composiciones farmaceuticas que los contienen y su uso. | |
| EA201000101A1 (ru) | Производные пиримидина 934 | |
| UY31750A (es) | Compuestos y composiciones como inhibidores de quinasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |